Seres therapeutics announces presentation of preliminary pk/pd and safety data for investigational microbiome therapeutic ser-155 at ash 2023

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling phase 1b study of ser-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-hct) will be presented at the 65th american society of hematology (ash) annual meeting held from december 9-12, 2023, in san diego, california, usa. ser-155 is an oral, cultivated live bacteria.
MCRB Ratings Summary
MCRB Quant Ranking